Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-20-010514
Filing Date
2020-05-13
Accepted
2020-05-13 09:35:18
Documents
59
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atos20200331_10q.htm 10-Q 698748
2 EXHIBIT 4.1 ex_183260.htm EX-4.1 41657
3 EXHIBIT 31.1 ex_181727.htm EX-31.1 11786
4 EXHIBIT 31.2 ex_181728.htm EX-31.2 12352
5 EXHIBIT 32.1 ex_181729.htm EX-32.1 6348
6 EXHIBIT 32.2 ex_181730.htm EX-32.2 6907
  Complete submission text file 0001437749-20-010514.txt   3313902

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT atos-20200331.xml EX-101.INS 480873
8 XBRL TAXONOMY EXTENSION SCHEMA atos-20200331.xsd EX-101.SCH 40693
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atos-20200331_cal.xml EX-101.CAL 28032
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20200331_def.xml EX-101.DEF 278711
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20200331_lab.xml EX-101.LAB 231883
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20200331_pre.xml EX-101.PRE 299234
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 20871345
SIC: 2834 Pharmaceutical Preparations